Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tetrabenazine MR in Subjects Aged 5 up to 17 Years With Tourette's Syndrome.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2019
Price :
$35
*
At a glance
- Drugs Tetrabenazine (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- 17 Nov 2010 Actual initiation date (Mar 2011) added as reported by ClinicalTrials.gov.
- 17 Nov 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 04 Jun 2010 New trial record